ERBB2 and breast carcinoma: As shown in Figure 4B, the fixed dose of tunicamycin at 1.0 μg/ml significantly enhanced trastuzumab-induced decreases of EGFR, HER2, HER3, Erk1/2 and Akt, as well as their phosphorylation levels in MCF-7/HER2 and SKBR3 cells, suggesting that MAPK and PI3K/Akt signaling pathways were greatly inhibited by the combination of tunicamycin and trastuzumab in HER2-overexpressing breast cancer cells.